Chilla et al. demonstrated that anti-VEGF agents could inhibit angiogenesis associated with mesenchymal migration but not amoeboid migration and suggested that the limited efficacy and resistance of single anti-VEGF agents in cancer therapy may in part be due to the drug-associated induction of MAT [31,32]. The gene discussed is VEGFA; the disease is cancer.